| Document |
Document Title |
|
WO/2016/115090A1 |
The present disclosure features compounds such as those having the Formulae (Ila), (lIb), (lIc), (Ild), (IlIa), and (Illb), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronc...
|
|
WO/2016/102488A1 |
The present invention relates to compounds of formula (I) wherein the variables are as defined in the claims and the description. The invention further relates to the use of these compounds for controlling invertebrate pests and to plant...
|
|
WO/2016/105485A2 |
The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
|
|
WO/2016/106133A1 |
Compounds and pharmaceutically acceptable salts and solvates thereof are described. The compounds relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology and organic chemistry.
|
|
WO/2016/097626A1 |
The invention relates to novel compounds, to the synthesis method thereof and to the use of same in medicine and in cosmetics. The invention relates to novel compounds, ligands that modulate RAR receptors.
|
|
WO/2016/097995A1 |
This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provi...
|
|
WO/2016/097389A1 |
The invention relates to benzenesulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan rece...
|
|
WO/2016/086722A1 |
Disclosed is a preparation method for an isoxazole compound and an intermediate thereof, the method comprising: a compound (I), as the starting material, is subjected to a substitution reaction with a compound (II) in the presence of a b...
|
|
WO/2016/090076A2 |
The present disclosure is directed dye compounds containing a hydrazinyl substituent and optionally, one or more negatively charged groups, such as sulfonate, phosphate, phosphonate, and/or carboxylate groups and dye compounds containing...
|
|
WO/2016/086136A1 |
The invention relates to fatty acid cysteamine conjugates of a CFTR modulator, compositions comprising a fatty acid cysteamine conjugate of a CFTR modulator, and methods for using such conjugates and compositions to treat disease, such a...
|
|
WO/2016/073633A1 |
The present technology relates to compounds of any one of Formula I, II, IIa, III, IV, and/or V as described herein and their tautomers and/or pharmaceutically acceptable salts, compositions, and methods of uses thereof.
|
|
WO/2016/062585A1 |
The present invention relates to a compound of formula (I) wherein: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are as defined herein; and wherein the compound of formula (I) is optionally present as an agrochemically acce...
|
|
WO/2016/047967A2 |
The present invention relates to an N-(5-arylamido-2-methylphenyl)-5-methylisoxazole-4-carboxami
de derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition including same. A compound according to the pr...
|
|
WO/2016/043975A1 |
The disclosure relates to various polymorphic forms and amorphous form of sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]is
oxazol-5-yl)amino)benzoate, including the polymorphic form A, mixtures of the polymorphs, proce...
|
|
WO/2016/037592A1 |
Disclosed are an aminosulfonyl compound represented by general formula I or a tautomer, enantiomer, racemate or pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition and a use thereof. The ...
|
|
WO/2015/196071A9 |
The present disclosure features disclosed compounds which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features method...
|
|
WO/2016/023787A1 |
The present invention relates to a process for the preparation of a compound of formula (I) wherein A1 and A2 are C-H, or one of A1 and A2 is C-H and the other is N; R1 is C1-C4alkyl, C1-C4haloalkyl or C3-C6cycloalkyl; each R2 is indepen...
|
|
WO/2016/017467A1 |
This noxious arthropod control agent, which contains an amide compound represented by formula (I) [In the formula, R1 represents a C1-C8 chain hydrocarbon group that may have one or more groups selected from group A, R2 represents a hydr...
|
|
WO/2016/018729A1 |
Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, wherein Dl, D2 and D3 are each N, CH, or substituted CH, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing ...
|
|
WO/2016/016162A1 |
The present invention relates to a compound of formula (I), wherein L is –C(O)NH-, -NHC(O)-, -S(O)2NH-, -NH- or -NHC(O)NH-; Ar is phenyl, benzyl, naphthyl or heteroaryl, selected from the group consisting of pyridinyl, pyrazolyl, pyrim...
|
|
WO/2016/017466A1 |
Provided is a noxious arthropod control agent containing an amide compound represented by formula (I) [In the formula, X represents a nitrogen atom or CH group, p represents 0 or 1, A represents a tetrahydrofuranyl group or the like, R1,...
|
|
WO/2016/013633A1 |
A compound represented by formula (I) or a salt thereof has an excellent noxious organism control activity, particularly an excellent miticidal activity and/or an excellent insecticidal activity, is highly safe, and can be synthesized in...
|
|
WO/2016/008433A1 |
Provided herein are novel substituted urea derivatives, and pharmaceutical compositions thereof. Also provided herein are uses of the compounds or pharmaceutical compositions thereof for preventing, managing, treating or lessening a prol...
|
|
WO/2015/196086A1 |
The present invention is directed to novel inhibitors of system Xc _, also known as the cystine/glutamate antiporter. The present invention is further directed to methods of treating and detecting cancer that overexpresses system Xc _ wh...
|
|
WO/2015/181189A1 |
The present invention relates to a novel process for preparing dihydroisoxazole derivatives.
|
|
WO/2015/181799A1 |
The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 is selected from methyl, pyrrolidinyl optionally substituted with one or more of fluorine, methyl and hydroxyl, piperidi...
|
|
WO/2015/170775A1 |
[Problem] To provide a novel substituted azole compound having a GPR119-activating activity and useful particularly for the prevention and/or treatment of diabetes and obesity. [Solution] Provided are: a novel substituted azole compound ...
|
|
WO/2015/166094A1 |
The present invention relates to processes for the preparation of substituted cycloserine compounds of formula (I) wherein R1 is C1-C8alkyl, C1-C8haloalkyl, C3-C6cycloalkyl,aryl or aryl substituted by one to five R11, or aryl-C1-C4alkyle...
|
|
WO/2015/164458A1 |
This invention pertains generally to compounds of Formula I and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention pertains to methods and c...
|
|
WO/2015/160636A1 |
In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said ...
|
|
WO/2015/160634A1 |
In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said ...
|
|
WO/2015/152254A1 |
The present invention provides a compound that has a strong α7 nicotinic acetylcholine receptor (α7 nAChR)-regulating effect and is useful as a therapeutic drug for diseases associated with cholinergicity of the central nervous system ...
|
|
WO/2015/143653A1 |
The present invention is directed to substituted five membered heteroaryl benzamide compounds compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of...
|
|
WO/2015/143300A1 |
The subject matter described here relates to the use of compounds and methods for the increase of progranulin expression. The methods may take place in vitro, ex vivo such as in isolates from adult mammalian tissue, or in vivo. Compounds...
|
|
WO/2015/138986A1 |
Novel FXR agonists are disclosed, embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subje...
|
|
WO/2015/132592A1 |
Disclosed herein are novel isoxazoline compounds of the general formula (I), compositions comprising these novel compounds, and uses of these compounds in the control of pests in both animal health and plant protection contexts. The comp...
|
|
WO/2015/127137A1 |
The present invention provides compounds of formula I that bind to mitochondrial aldehyde dehydrogenase-2 (ALDH2), and methods of using said compounds to treat patients with i.a. cancer, Fanconi anemia and alcohol-related disorders. [For...
|
|
WO/2015/124101A1 |
The present invention relates to a naphthylamide compound of the structure as represented by formula (I), medicinal salts, prodrugs and hydrates or solvates thereof, and also relates to a method of preparing the compounds, pharmaceutical...
|
|
WO/2015/122188A1 |
A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the...
|
|
WO/2015/121212A1 |
Compounds of formula (I), wherein Z = cyclopentyl. cyclopropylmethyl, -CH3; R' = -CH3, CHF2, X= formula (II) (III) (IV) (V) Y = - CO; -C=O(CH2), -CH(OH)-CH2, -CH2-C=O, -CH2-CH2-C=O; -CH2-CH(OH)-CH2, -CH2- CH(OCOR1)-CH2 NR2 = -N(CH2-CH2OH...
|
|
WO/2015/122508A1 |
An isoxazoline compound represented by formula (12) can be manufactured via a compound represented by formula (7) by using a compound represented by formula (1) (in the formulas, R1 represents a hydrogen atom or a halogen atom, R5 repres...
|
|
WO/2015/117912A1 |
Compounds of formula (I), wherein (II) is a five-membered, aromatic ring system which may contain 2 or 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulphur,and where each ring system may not contain more than ...
|
|
WO/2015/116846A1 |
Compositions and methods are provided for modulating the physiological activation of tissue transglutaminase (TG2); which methods can include inhibiting the activity of TG2 associated with inflammatory disorders, which disorders may incl...
|
|
WO/2015/116760A1 |
In one aspect, the invention relates to compounds having the formula (I): where R1, R2a, R2b, and R3-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activi...
|
|
WO/2015/116786A1 |
In one aspect, the invention relates to compounds having the formula (I): where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another asp...
|
|
WO/2015/112014A1 |
The present invention relates to a process comprising the step of reacting a (hetero)aryl 1,3-dipole compound with a (hetero)cycloalkyne, wherein: a (hetero)aryl 1,3-dipole compound is defined as a compound comprising a 1,3-dipole functi...
|
|
WO/2015/112079A1 |
The present invention relates to methods for inhibiting the activity of human kallikrein 7 (KLK7) (also known as serine protease stratum corneum chymotryptic enzyme, SCCE). The invention further relates to the use of KLK7 inhibitors of F...
|
|
WO/2015/109210A1 |
The disclosed subject matter provides N-hydroxymethanesulfonamide compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed...
|
|
WO/2015/094670A1 |
The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the c...
|
|
WO/2015/087857A1 |
Provided is an aryl amidine compound that has excellent bactericidal activity, is highly safe, can be synthesized in an industrially advantageous manner, and is represented by formula (II) or the like. Also provided is a bactericidal age...
|
